Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

This publication has 23 references indexed in Scilit:

• Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
  Journal of Clinical Oncology, 2010
• Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches
  Leukemia & Lymphoma, 2010
• High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
  British Journal of Haematology, 2008
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• Improved survival in multiple myeloma and the impact of novel therapies
  Blood, 2008
• International uniform response criteria for multiple myeloma
  Leukemia, 2006
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• International Staging System for Multiple Myeloma
  Journal of Clinical Oncology, 2005
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
  British Journal of Haematology, 2004
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998